Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
DaShenLin Pharmaceutical Group Co ROE % Adjusted to Book Value Chart
DaShenLin Pharmaceutical Group Co ROE % Adjusted to Book Value Competitor Comparison
For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
DaShenLin Pharmaceutical Group Co ROE % Adjusted to Book Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where DaShenLin Pharmaceutical Group Co's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 10.44% mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a ROE % Adjusted to Book Value of 10.44% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DaShenLin Pharmaceutical Group Co and its competitors.
Is DaShenLin Pharmaceutical Group Co's ROE % Adjusted to Book Value too high?
DaShenLin Pharmaceutical Group Co's current ROE % Adjusted to Book Value is 10.44%. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's ROE % Adjusted to Book Value compare to competitors?
DaShenLin Pharmaceutical Group Co's ROE % Adjusted to Book Value of 10.44% can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Healthcare Providers & Services company?
A good ROE % Adjusted to Book Value depends on the Healthcare Providers & Services industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. DaShenLin Pharmaceutical Group Co's current ROE % Adjusted to Book Value is 10.44%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.81, compared to a current price of ¥19.25 — trading 2.3% above its estimated fair value. The current ROE % Adjusted to Book Value is 10.44%. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 94/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current ROE % Adjusted to Book Value is 10.44% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be overvalued.
The current stock price of ¥19.25 is trading 2.3% above its estimated GF Value™ of ¥18.81.
GuruFocus considers DaShenLin Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:603233:
ROE % Adjusted to Book Value: 10.44%
GF Value™: ¥18.81 vs. price of ¥19.25 (2.3% above fair value)
No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
DaShenLin Pharmaceutical Group Co Business Description
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
94GF Score
Get the complete analysis for SHSE:603233
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603233 has been successfully added to your 
